Windtree Therapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Windtree Therapeutics sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 5 completed early-phase tilt top decile by trial count

Windtree Therapeutics: 11 sponsored US clinical trials, none currently recruiting.

Windtree Therapeutics sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 5 completed. 1 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Respiratory Distress Syndrome, with 1 trials.

Top-decile sponsor footprint

Windtree Therapeutics ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

5 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

11 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 1

A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C

NCT05975021
COMPLETED Phase 2

The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19)

NCT04389671
COMPLETED Phase 2

The Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock

NCT04325035
COMPLETED Phase 2

The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age

NCT02636868
TERMINATED Phase 2

Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

NCT02528318
COMPLETED Phase 2

Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates

NCT02074059
COMPLETED Phase 2

Lucinactant for Treatment of Acute Hypoxemic Respiratory Failure in Children up to Two Years Old

NCT00578734
TERMINATED Phase 2

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

NCT00215540
TERMINATED Phase 2

Feasibility Study of Aerosolized Surfaxin in the Prevention of Respiratory Distress Syndrome (RDS) in Premature Infants

NCT00807235
TERMINATED Phase 2

KL₄Surfactant Treatment in Patients With ARDS

NCT00215553
TERMINATED Phase 3

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

NCT00004500

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 9
Phase 3 1

Therapeutic Areas

Respiratory Distress Syndrome 1
Cardiogenic Shock 1

How the Windtree Therapeutics early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 5 completed (45%).

Phase mix: 1 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Respiratory Distress Syndrome (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Windtree Therapeutics: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Windtree Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Windtree TherapeuticsAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Windtree Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Windtree Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Windtree Therapeutics page

11 registered trials is a research-attention snapshot, not an endorsement of Windtree Therapeutics or any single study.

  • None of Windtree Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Respiratory Distress Syndrome is the condition Windtree Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Respiratory Distress Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Windtree Therapeutics pipeline card: 11 registered trials from official public datasets.Report a data error.